Basavilvazo-Rodríguez A, Bravo-Rodríguez LM, Carranza-Lira S, Celis-González C, Hernández MI, Hernández-Valencia M, López NME, Maldonado AJD, Montaño UJA, Moreno AÁJ, Vázquez G

Language: Spanish
References: 25
Page: 467-472
PDF size: 809.77 Kb.

ABSTRACT

Vasomotor symptoms are one of the main reasons for climateric women to consult a physician. Hormone therapy is the first treatment choice, but it is not indicated to all patients. Veralipride is an option for those who cannot or will not try hormone treatment. The Mexican Association for the Study of Climateric (AMEC) assembled an interdisciplinary group of medical experts so that they revised the medical literature on the subject and reached a consensus on veralipride indication, doses, counterindications and safety. The recommendations of the Consensus conference on veralipride are: 1. Physicians must be familiar with its indication, side effects, pharmacokinetics and dosage. 2. Patients must be informed on other therapeutical options. 3. Patients’ mental and neurological state must be evaluated, in particular to identify movement disorders, extrapyramidal symptoms (tremor or dystonia), anxiety and depression that can be mistaken for clmateric symptoms. 4. Any adverse effect associated with the drug must be reported. 5. A random multicenter trial must be carried out in order to identify the frequency and severity of side effects, and 6. Written information on possible health risks when using the drug must be provided.

REFERENCES

1. Rodstrom K, Bengtsson C, Lissner L, Milsom I, Sundh V, Bjorkelund C. A longitudinal study of the treatment of hot flushes: the population study of women in Gothenburg during a quarter of a century. Menopause 2002;9:156-161.

2. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 1985;8:261-268.

3. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci 1990;592:52-86.

4. Freedman RR. Biochemical metabolic, and vascular mechanisms in menopausal hot flushes. Fertil Steril 1998;70:332-337.

5. Freedman RR, Norton O, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flushes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-2358.

6. Savage MV, Brengelmann GL. Control of skin blood flow in the neutral zone of human body temperature regulation. J Appl PhysioI1996;80:1249-1257.

7. Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Sys Rev 2004;(4):CD002978.

8. Carranza-Lira S, Cortés-Fuentes E. Modification of vasomotor symptoms after various treatment modalities in the postmenopause. Int J Gynaecol Obstet 2001;73:169- 171.

9. Reddy SY, Warner H, Guttuso T, Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol 2006; 1 08:41-48.

10. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827- 2834.

11. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-166.

12. Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22:94-97.

13. Archer DF, Dupont CM, Constantine GD, Pickar JH, Olivier S. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. Am J Obstet Gynecol 2009;200:238.e1-238.e10.

14. De Leo V, Morgante G, Musacchio MC, Faldini E, Delia A, Petraglia F. The safety of veralipride. Expert Opin Drug Saf 2006;5:695-701.

15. Carretti N, Florio P, Reis FM, Comai S, Bertazzo A, Petraglia F. Reduction of serum serotonin precursors after veralipride treatment for postmenopausal hot flushes. Climacteric 2010;13:141-146. European Medicines Agency. Doc Ref.EMEA/299873/2007.

16. World Health Organization. More risks tan benefits with veralipide; marketing authorization withdrawn for all medicinal products containing veralipride. QSM/MC/IEA 11.6. 23 july 2007.

17. http://www.cofepris.gob.mx/AZ/Paginas/Farmacovigilancia/Comunicados.aspx

18. David A, Don R, Tajchner G, Weissglas L. Veralipride: Alternative antidopaminergic treatment for menopausal symptoms. Am J Obstet Gynecol 1988;158:1107-1115.

19. Wesel S, Bourguignon RP, Bosuma WB. Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flashes. Curr Med Res Opin 1984;8:696-700.

20. Melis GB, Gambacciani M, Cagnacci A, Paoletti AM, Mais V, Fioretti P. Effects of dopamine antagonist veralipride on hot flashes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol 1988;72:688-692.

21. Boukobza G. Efficacité et tolérance du veralipride dans le traitement des bouffes de chaleur de la ménopause. Étude multicentrique. Rev Fr Gynecol Obstet 1986;81:413- 417.

22. Vercellini P, Vendola N, Colombo A, Passadore C, Trespidi L, Crosigniani PG. Veralipride for hot flashes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest 1992;34:102-104.

23. Masmoudi K, Gras-Champel V, Lemaire-Hurtel AS, Masson H, Munier A, Geslin JM, et al. Troubles extrapyramidaux sous véralipride (Agréal®), traitement symptomatique des bouffées de chaleur: à propos de 17 cas. Rev Med Interne 2005;26:453-457.

24. Nelson HD Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Therapies for menopausal hot flashes systematic review and meta-analysis. JAMA 2006;295:2057-2071.

25. Dargent O, Dumont M, Malinas Y. Etude de I’efficacité et de la tolérance clinique et biologique du veralipride administre au long cours. A propos de soixante-quatorze observations. Sem Hop 1983;59:2778-2780.